Alkermes PLC
Latest Alkermes PLC News and Updates
What Does Nektar Therapeutics’ Valuation Trend Indicate?
Under its immunology program, Nektar Therapeutics (NKTR) is developing NKTR-358 in collaboration with Eli Lilly and Company (LLY).
An Insight into Alkermes’ R&D Pipeline
Alkermes’ ALKS3831 is an investigational oral medicine is targeted for the treatment of schizophrenia.
Alkermes’s Aristada and Its FDA Approval for Schizophrenia
Aristada was approved by the FDA and is projected to account for 10% to 30% of the LAI atypical antipsychotic market for schizophrenia patients in the US.